Angiocrine Bioscience   Report issue

For profit Phase 1
Founded: New York NY United States (2012)

Organization Overview

First Clinical Trial
2018
NCT03483324
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Angiocrine Bioscience